Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Propanc Biopharma ( (PPCB) ) is now available.
On June 12, 2025, Propanc Biopharma entered into a securities purchase agreement with an investor for a convertible promissory note worth $25,000, intended for general working capital. The note, convertible into common stock, has a maturity date of June 12, 2026, and bears an 8% annual interest. Additionally, on June 13, 2025, the company secured a loan of $13,188 AUD from a board member, also for working capital, with a 12% annual interest rate and a maturity date of June 30, 2025. These financial moves aim to bolster the company’s operational funds and potentially impact its market positioning.
More about Propanc Biopharma
Propanc Biopharma, Inc. operates in the biopharmaceutical industry, focusing on the development of cancer treatments. The company primarily works on therapies aimed at preventing cancer recurrence and metastasis, targeting a significant market need in oncology.
Average Trading Volume: 2,159
Technical Sentiment Signal: Strong Sell
Current Market Cap: $59.22M
For a thorough assessment of PPCB stock, go to TipRanks’ Stock Analysis page.